Treatment Options for HER2-Low Breast Cancer: All You Need to Know

Antibody-Drug Conjugates for HER2-Low Disease: 2023 KU Breast Cancer Year in Review

ENHERTU Therapy: A Powerful New Cancer Treatment

The exciting new field of HER2-low breast cancer

Is HER2-low a distinct subtype of breast cancer?

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJM

Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate

HER2-Low Breast Cancer: DESTINY or Good Science?

New treatment for HER2 low metastatic breast cancer (HB 422)

FDA Approves First Companion Diagnostic for HER2 Low Metastatic Breast Cancer

TALENT: neoadjuvant T-DXd with or without anastrozole for HER2-low, HR+ early stage breast cancer

Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC

ADCs for HER2+ and HER2-low breast cancer

FDA D.I.S.C.O. Burst Edition: FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for unr...

PFS Data Support Approval of Fam-Trastuzumab Deruxtecan-nxki for HER2+ Breast Cancer

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression

METASTATIC BREAST CANCER: ENHERTU STOPS THE SPREAD

HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More Patients

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement

DESTINY-Breast04: T-DXd for patients with HER2-low mBC